Login to Your Account

NewCo News: DecImmune Taking a Fresh Approach to Reperfusion Injury

By Catherine Shaffer

Wednesday, March 9, 2011
Tissue damage following cardiac arrest or other cardiovascular events is an ongoing problem with great unmet need. DecImmune Therapeutics Inc. is a new biotechnology company focused on developing peptide and antibody therapeutics for acute inflammation and tissue damage following vascular injury by way of the N2-IgM pathway.

To continue reading subscribe now to BioWorld Today

Learn More about BioWorld Today

Already a subscriber? Sign In or Buy now to activate your subscription